Regression of left ventricular hypertrophy in human hypertension with irbesartan
Journal of Hypertension2001Vol. 19(6), pp. 1167–1176
Citations Over TimeTop 10% of 2001 papers
Karin Malmqvist, Thomas Kahan, Magnus Edner, Claes Held, Anders Hägg, Lars Lind, Richard Müller-Brunotte, Fredrik H. Nyström, K. Peter Öhman, Mary Osbakken, Jan Östergren
Abstract
Left ventricular mass was reduced more in the irbesartan group than in the atenolol group. These results suggest that blocking the action of angiotensin II at AT1-receptors may be an important mechanism, beyond that of lowering blood pressure, in the regulation of left ventricular mass and geometry in patients with hypertension.
Related Papers
- Therapeutic effect of domestic Irbesartan/hydrochlorothiazide on primary hypertension.(2010)
- Clinical Observation of Irbesartan and Hydrochlorothiazide Irbesartan on the Treatment of Essential Hypertension(2012)
- The Effect of Irbesartan and Hydrochlorothiazide in the Treatment of Essential Hypertension(2008)
- Clinical evaluation of irbesartan and hydrochlorothiazide irbesartan on the treatment of essential hypertension(2011)
- The Analysis of Controlling Rate of Irbesartan/Hydrochlorothiazide Combination over Mild to Moderate Hypertension(2008)